<?xml version="1.0" encoding="UTF-8"?>
<p id="Par30">Hepatocellular carcinoma (HCC) is the sixth commonest and third most lethal solid malignancy on a global scale [
 <xref ref-type="bibr" rid="CR1">1</xref>]. In spite of the major diagnostic advancements, only one out of three of the newly diagnosed patients are eligible for radical treatments upfront [
 <xref ref-type="bibr" rid="CR2">2</xref>]. In patients within the Barcelona Clinic Liver Cancer (BCLC) stage 0 or A criteria, surgical resection can be carried out safely with curative intent [
 <xref ref-type="bibr" rid="CR3">3</xref>]. However, this is only feasible in &lt;â€‰30% of the patients, mainly due to the extent of radiological spread of the disease or poor synthetic function due to underlying cirrhosis.
</p>
